Japanese Dermatological Association Guidelines: Guidelines for the treatment of acne vulgaris 2017. Issue 8 (21st May 2018)

• Record Type: Journal Article
• Authors: Hayashi, Nobukazu; Akamatsu, Hirohiko; Iwatsuki, Keiji; Shimada‐Omori, Ryoko; Kaminaka, Chikako; Kurokawa, Ichiro; Kono, Takeshi; Kobayashi, Miwa; Tanioka, Miki; Furukawa, Fukumi; Furumura, Minao; Yamasaki, Osamu; Yamasaki, Kenshi; Yamamoto, Yuki; Miyachi, Yoshiki; Kawashima, Makoto
• Is Part Of: Journal of dermatology. Volume 45:Issue 8(2018)
• Page Start: 898
• Page End: 935
• Publication Date: 2018-05-21
• Subjects: acne vulgaris -- antimicrobial resistant -- guideline -- maintenance therapy -- Propionibacterium acnes; Dermatology -- Periodicals; Dermatology -- Japan -- Periodicals; Skin -- Diseases -- Periodicals; 616.5005
• DOI: 10.1111/1346-8138.14355
• Languages: English
• ISSNs: 0385-2407

Abstract

Abstract: The Guidelines for the Treatment of Acne Vulgaris of the Japanese Dermatological Association was first published in Japanese in 2008 and revised in 2016 and 2017. These guidelines (GL) indicate the standard acne treatments in Japan and address pharmaceutical drugs and treatments applicable or in use in Japan. In these GL, the strength of the recommendation is based on clinical evidences as well as availability in Japanese medical institutions. In the 2016 and 2017 GL, some of the clinical questions were revised, and other questions were added in accordance with approval of topical medicines containing benzoyl peroxide (BPO). Rather than monotherapies of antibiotics, the 2017 GL more strongly recommend combination therapies, especially fixed‐dose combination gels including BPO in the aspects of pharmacological actions and compliance in the acute inflammatory phase to achieve earlier and better improvements. The 2017 GL also indicate to limit the antimicrobial treatments for the acute inflammatory phase up to approximately 3 months and recommend BPO, adapalene, and a fixed‐dose combination gel of 0.1% adapalene and 2.5% BPO for the maintenance phase to avoid the emergence of antimicrobial‐resistant Propionibacterium acnes . The 2017 GL also discuss rosacea, which requires discrimination from acne and a different treatment plan.